Objective: To evaluate the whole experience of liver transplantation (LT) with donors !70 years in a single center not applying specific donor/recipient matching criteria. Background: LT with very old donors has historically been associated with poorer outcomes. With the increasing average donor age and the advent of Model for End-stage Liver Diseases (MELD) score-based allocation criteria, an optimal donor/recipient matching is often unsuitable. Methods: Outcomes of all types of LTs were compared according to 4 study groups: patients transplanted between 1998 and 2003 with donors <70 (group 1, n ¼ 396) or !70 years (group 2, n ¼ 88); patients transplanted between 2004 and 2010 with donors <70 (group 3, n ¼ 409), or !70 years (group 4, n ¼ 190). From 2003, graft histology was routinely available before crossclamping, and MELD-driven allocation was adopted. Results: Groups 1 and 2 were similar for main donor and recipient variables, and surgical details. Group 4 had shorter donor ICU stay, lower rate of moderate-to-severe graft macrosteatosis (2.3% vs 8%), and higher recipient MELD score (22 vs 19) versus group 3. After 2003, median donor age, recipient age, and MELD score significantly increased, whereas moderate-tosevere macrosteatosis and ischemia time decreased. Five-year graft survival was 63.6% in group 1 versus 59.1% in group 2 (P ¼ 0.252) and 70.9% in group 3 versus 67.6% in group 4 (P ¼ 0.129). Transplants performed between 1998 and 2003, recipient HCV infection, balance of risk score >18, and pre-LT renal replacement treatments were independently associated with worse graft survival. Conclusions: Even without specific donor/recipient matching criteria, the outcomes of LT with donors !70 and <70 years are comparable with appropriate donor management.
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Different ways of overcoming this gap have been progressively explored, some of them becoming well-accepted strategies, such as split LT, living-donor LT, and transplantation with donors after circulatory death. 1 Among donors carrying one or more risk factors for poor LT outcome-the so-called extended criteria donors (ECDs) -the use of old donors has long been recognized as the most immediate solution. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] Several groups, including ours, reported acceptable or even excellent short and middle-term results by using very aged donors for LT, thus supporting this strategy in a context of ageing general population. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] However, some shadows still remain when pushing the donor age limits. The best results have been obtained when favorable donor/ recipient matching has been adopted, generally signifying that ECDs should properly be allocated to LT candidates able to tolerate suboptimal allograft function recovery, that is, young recipients, patients with low Model for End-stage Liver Diseases (MELD) score and/or expected technically uneventful LT procedures. 8, 10, 12, 13, [15] [16] [17] Recent predictive models matching donor and recipient characteristics seem to validate these concepts. [18] [19] [20] [21] Unfortunately, the organizational ''milieu,'' in which this approach should be implemented, is not always favorable. In regions where strict allocation criteria are adopted, especially after the advent of MELD-based systems, the assignment of an organ transplanted from an old donor to the ideal recipient is often a challenging task. Since ECDs represent a considerable and increasing proportion of the donor pool, the combination with the adoption of MELD-based allocation criteria at a national level has led to inferior results compared with previous LT outcomes. 22 Secondarily, long-term outcomes of LT with older donors have been demonstrated to be generally inferior to those obtained with younger donors, especially because they are affected by a higher prevalence of hepatic disease recurrence, namely hepatitis C virus (HCV). 7, 23 Although newer antiviral drugs are expected to drastically decrease posttransplant HCV recurrence, the magnitude of this positive effect when matched with the usage of ECDs is currently unknown.
The real longevity of a liver allograft with diminished regenerative capacities, 24, 25 and the possible negative impact of advanced donor age on the recurrence of malignancies, such as hepatocellular carcinoma (HCC), 26 represent other possible unfavorable factors.
Our center has extensive long-term experience in the utilization of older donors, 2, 3, 7, 9 and works within the first Italian region which has adopted a MELD-based allocation of liver allografts since 2004. In the present study, we aimed to investigate the actual risk of
METHODS
From January 1, 1998 to December 31, 2010, 979 patients received a total of 1083 LTs from ABO-identical or ABO-compatible brain death-deceased donors at our center. The start of the study was chosen based on the date of the first use of a donor older than 70 years.
During the study period, almost all LTs were performed with the piggyback technique. 27 Cell-saver was used intraoperatively, but the volume of the reinfused blood was computed in the total of red blood cells (RBCs) transfused.
The initial immunosuppression was based on calcineurin inhibitors (CNIs) in combination with steroids, as previously reported. 3, [28] [29] [30] [31] The preferred CNI was cyclosporine until the early 2000, and tacrolimus thereafter. Induction immunosuppression with antithymocite globulins, basiliximab, daclizumab, or alemtuzumab was used in 151 (13.9%) cases.
Delayed graft function (DGF) and primary nonfunction (PNF) were treated with infusion of prostaglandin E1 (PGE1), when clinically feasible. 32 Rejection episodes were treated with methylprednisolone pulse doses, with monoclonal antibodies reserved for cases of steroid-resistant rejection.
Post-LT liver disease recurrences were always histologically proven. 33 No preemptive antiviral protocols were adopted in HCVpositive patients. In the case of HCV recurrence, antiviral treatment with interferon and ribavirin was offered to all patients, in the absence of contraindications. It was continued for at least 6 months and until a virological and biochemical response was obtained. 34 
Allocation Criteria and Policy of Acceptance of Liver Allografts for LT
Before 2004, liver allografts were allocated to recipients essentially based on the Child-Pugh score and the UNOS status at a single-center level. Patients without liver decompensation as the main indication for LT were not given preestablished extra points while on the waiting list, but were prioritized on a case-by-case multidisciplinary judgment. 28 Since 2004, a 2-center regional allocation based on MELD score has been adopted, with extra points assigned a priori for special indications (HCC, metabolic diseases, combined transplants, etc), with periodical reevaluation between the 2 programs involved. 28, 29, 35 Before 2004, there were no fixed indications for rejecting or accepting livers from old donors. Pre-LT donor liver biopsy was not routinely performed, but only according to the judgment of the surgeon on duty for organ procurement. The presence of macrosteatosis exceeding 30% of the parenchyma, bridging lobular necrosis, severe portal inflammation, and fibrosis stage >2 according to the Ishak score, 36 were absolute contraindications for LT. 9 From the end of 2003, our policy changed to systematically performing liver needle biopsy in all donors older than 60 years, immediately after donor laparotomy, with donor aorta cross-clamping and recipient procedure starting just after communication of the pathology report. This led to: minimizing the time of back-table preparation of the graft, which could be almost completely dissected free before cold perfusion, while waiting for hepatic histology; complete assessment of donor risk, virtually eliminating cases in which a final decision on the use of the graft had to be taken at its arrival at the site of LT; and keeping cold ischemia time (CIT) reasonably short, as the LT procedure could be started before the graft arrival. 9 Irrespective of donor age, histological criteria representing absolute contraindications for LT remained unchanged. Some liver grafts with macrovesicular steatosis >30% were accepted for LT, in the absence of other significant alterations, especially if the graft-torecipient size ratio greatly exceeded 1, with an expected sufficient amount of functional hepatocytes.
Unlike other centers, we do not have quantitative cut-off values for discarding donors with elevated transaminases, histological necrosis, or severe atherosclerosis of the hepatic artery (HA). 15 Atherosclerosis of the donor HA itself has never been a contraindication for LT. In cases where the common HA was unsuitable for anastomosis, we used the proper HA or the gastroduodenal artery; on the other hand, we never encountered a proper HA so massively altered as to be unsuitable for LT.
Hepatitis B anticore (HBcAb)-positive and hepatitis B surface antigen (HBsAg)-positive donors were allocated without specific patient selection, and to HBsAg-positive/hepatitis delta-negative patients, respectively, with proper post-LT antiviral prophylaxis. HCV-positive donors were used for HCV-positive recipients. 37 In such cases, liver biopsy was routinely performed, regardless of donor age.
Study Design
The patient population was divided into 2 categories of donor age, that is donors <70 years (n ¼ 805), and those aged 70 years or more (n ¼ 278). Given the changes in the center's policies after 2003, we also compared the results obtained in 2 consecutive time periods: 1998 to 2003 (period 1) and 2004 to 2010 (period 2). Thus, we considered 4 study groups: patients transplanted with donors <70 years in period 1 (group 1, n ¼ 396), those transplanted with donors !70 years in period 1 (group 2, n ¼ 88), those transplanted with donors <70 years in period 2 (group 3, n ¼ 409), and those transplanted with donors !70 years in period 2 (group 4, n ¼ 190).
The results were retrospectively analyzed with a prospectively updated database. Most relevant donor and recipient-related demographic, clinical, biochemical, and technical factors were analyzed and compared between the 2 study groups. To evaluate the suitability of donor/recipient matching, the donor-MELD (D-MELD, ie the product of donor age by recipient MELD), 19, 20 the Donor Risk Index (DRI), 38 and the Balance of Risk (BAR) score 21 were retrospectively calculated and compared between the groups.
Results were evaluated in terms of posttransplant survival rates and complications, considering grade III and IV complications according to the Dindo-Clavien classification. 39 Postoperative course was defined as the period of 90 days after LT. Chronic kidney disease was defined as 2 estimated glomerular filtration rate readings <60 mL/min/1.73 m 2 , separated by 3 months. 40 This study was approved by the Institutional Review Board of our hospital.
Statistical Analysis
Results are expressed as median and range of values. Differences between continuous and categorical variables were calculated with the Mann-Whitney U test and the chi-square test or Fisher exact test, respectively.
The continuous variables were analyzed using the following cut-off sets:
1. Donor variables: age </!70 years, ICU stay />5 days, 31 body mass index (BMI) </!30 kg/m 2 , 38 macrovesicular steatosis </!30%, 9 fibrosis stage />1, 9 transaminases peak />200 U/L, 41 total bilirubin />2 mg/dL, 41 serum sodium />170 mEq/L, 19 CIT />8 hours, DRI />1.8. 38 2. Recipient variables: age </!55 years (median age of the study population), BMI </!25 kg/m 2 (median BMI of the study population), MELD score </!30, 42 D-MELD />1628, 20 BAR score />18, 21 RBC transfusion during LT </!2000 mL. 43 Graft survival rate was calculated from the date of LT to the date of the last check-up, patient death, or graft loss. Patient survival was calculated from LT to the last check-up or patient death. Actuarial survivals were computed with the Kaplan-Meier method, and the differences between groups were compared by the log-rank test. Logistic regression was used for multivariate analysis of risk factors for lower graft survival.
A P value less than 0.05 was considered statistically significant. Statistical analysis was carried out with the SPSS software packaging, version 17.0 (SPSS, Inc., Chicago, IL).
RESULTS

Profiles of Donors, Recipients, and LT Technical Details in Period 1
Characteristics of group 1 and 2 donors are reported in Table 1 . Older donors had a significantly higher incidence of cerebrovascular cause of death, higher BMI, and prevalence of diabetes. Liver biopsy was more frequently performed in group 2 (60.2% vs 16.9%; P < 0.001). In contrast, younger donors had a significantly higher incidence of cardiac arrests and hypertransaminasemia. The median CIT was comparable between groups, with 39.4% and 47.7% of groups 1 and 2, respectively, having CIT >8 hours. As expected, group 2 had higher median DRI and proportion of DRI >1.8 (74.1% vs 10.1%; P < 0.001).
The characteristics of recipients and transplants are reported in Table 2 . Group 2 recipients were older than group 1 recipients. Except for retransplantation, indications for LT were comparable between groups. Median MELD and BAR scores at transplant, prevalence of hepatorenal syndrome (HRS), previous supramesocolic surgery, rates of portal vein thrombosis, pre-LT need for intensive supports (ie, mechanical ventilation [MV], continuous venovenous hemofiltration [CVVH]/hemodialysis [HD], norepinephrine infusion), duration of LT procedures, need for RBC transfusions, and use of PGE1 after transplant were comparable between groups. Conversely, D-MELD score was higher in group 2. Finally, Group 2 recipients received induction immunosuppression more frequently.
Profiles of Donors, Recipients, and LT Technical Details in Period 2
As reported in Table 3 , during the more recent period, older donors were more frequently female, had a higher incidence of cerebrovascular cause of death, shorter ICU stay, higher BMI, and prevalence of arterial hypertension, renal diseases, and diabetes. Liver biopsy was performed in 48.7% and 90.0% of cases in groups 3 and 4, respectively (P < 0.001), with a lower prevalence of macrovesicular steatosis !30% in group 4. In contrast, younger donors had a significantly higher incidence of cardiac arrests, hypotensive episodes, and hypertransaminasemia. The median CIT was comparable between groups, but less than 9% of cases in both groups had CIT >8 hours. Again, older donors had higher DRI.
Overall, older donor age, higher prevalence of HBcAb, HBsAg, HCV-positive donors, longer ICU stay, higher BMI, higher prevalence of arterial hypertension and of renal diseases, lower use of norepinephrine, higher number of graft biopsies, fewer cases of macrosteatosis !30%, higher rate of fibrosis stage >1, and shorter CIT were recorded in period 2 versus period 1 (P < 0.05 for all comparisons).
Groups 3 and 4 patients' demographic profiles and indications for LT were similar (Table 4) . Group 4 had a lower rate of combined transplants, but higher median D-MELD, MELD, and BAR scores. Of note, almost 50% of group 4 patients had D-MELD >1628. 20 Finally, Group 4 patients were more frequently treated with induction immunosuppression (Table 4) .
Overall, in period 2, LT recipients were older; HCC and cholestatic diseases as the indication for LT increased, whereas postnecrotic cirrhosis and retransplantations decreased; combined transplants increased. Median D-MELD, MELD, and BAR scores, prevalence of HRS, need for pre-LT ICU admission, pre-LT CVVH/ HD requirement, rate of previous supramesocolic surgery, of post-LT PGE1 infusion, and of induction immunosuppression increased, whereas LT procedure duration and need for intraoperative hemotransfusions significantly decreased (P < 0.05 for all comparisons).
Causes of Graft Loss and Survival
After a median follow-up time of 87 months (0-204 mo), 431 grafts (39.7%) were lost. One and 5-year graft survival rates were 76.0% and 63.6% in group 1, 78.4% and 59.1% in group 2, 82.1% and 70.9% in group 3, and 74.6% and 67.6% in Group 4 (P ¼ 0.009) (Fig. 1 ). There were no statistical differences between groups 1 and 2 (P ¼ 0.252), or between groups 3 and 4 (P ¼ 0.129). Corresponding patient survival rates were 81.6% and 69.7% in group 1, 85.2% and 64.8% in group 2, 85.7% and 74.1% in group 3, and 79.6% and 72.0% in group 4 (P ¼ 0.063).
One and 5-year graft survival rates were 76.7% and 62.8% in period 1, and 79.8% and 69.7% in period 2 (P ¼ 0.04). Corresponding patient survival rates were 82.2% and 68.8%, and 83.8% and 73.4%, respectively (P ¼ 0.039).
Excluding a higher prevalence of de novo tumors in Group 2 vs Group 1, there were no significant differences in causes of graft loss between recipients of older and younger grafts in either of the 2 study periods (Table 5) . Overall, the main cause of graft loss was HCV recurrence (23.9% of the cases), followed by infection/ multiorgan failure (MOF) (22.0%), PNF/DGF (10.4%), and vascular complications (9.5%). HCV and vascular-related graft losses decreased, whereas HCC recurrence significantly increased in period 2 (P < 0.05 for all comparisons).
Considering the 541 HCV-positive patients separately, 1 and 5-year graft survival rates were 72.0% and 55.9% in group 1, 75.6% and 51.1% in group 2, 79.7% and 66.1% in group 3, and 78.5% and 65.5% in group 4 (P ¼ 0.006). Corresponding patient survival rates were 76.8% and 60.7% in group 1, 84.4% and 57.8% in group 2, 83.3% and 69.3% in group 3, and 82.8% and 69.8% in group 4 (P ¼ 0.018).
In the same category of patients, 1 and 5-year graft survival rates were 76.8% and 61.5% in recipients with D-MELD 1750, and 78.4% and 59.4% in those with D-MELD >1750 (P ¼ 0.933), whereas 1 and 5-year patient survival rates were 82.4% and 66.4%, and 79.7% and 62.1%, respectively (P ¼ 0.527). 20 
Postoperative Complications
As reported in Table 6 , there were no significant differences in grade III to IV postoperative complications, duration of hospitalization, incidence of chronic kidney disease, or incidence, treatment, and outcome of long-term biliary complications between groups 1 and 2. Chronic HD requirement was more frequent in Group 2 vs Group 1.
With the exception of a higher incidence of grade III ascites/ pleural effusion in group 4, there were no significant differences in grade III to IV postoperative complications, duration of hospitalization, or incidence, treatment, and outcome of long-term biliary complications between groups 3 and 4. However, chronic kidney disease and HD requirement were more frequent in group 3.
Overall, in period 2, vascular complications and ascites/pleural effusion decreased, whereas other complications requiring intervention and length of ICU stay significantly increased. In general, long-term biliary complications increased over time, but their treatment was successful in a comparable number of cases. Finally, though renal impairment was less frequent in period 2, the requirement of HD increased in the second era (P < 0.05 for all comparisons).
Analysis of Factors Affecting Graft Survival
The variables reported in Tables 1 to 4 
DISCUSSION
This study confirms previous findings that advanced donor age is not per se detrimental for patient outcome, provided that certain principles of graft protection and minimization of other risk factors are fulfilled. 2, 3, 5, 7, [8] [9] [10] [11] [12] [13] 15, 16 In the more recent period of our experience, we tried to systematically apply these principles, consisting in discarding grafts with moderate-to-severe macrosteatosis, fibrosis, and necrosis through a routine liver graft biopsy, and to minimize the ischemia time. Data from our experience and from other studies suggest that CIT 8 hours is a prerequisite for the safe use of older donors. 2,3,5,7,8 -10,12,13,15,16 On the other hand, selection of older donors without marked liver parenchymal alterations has been shown to determine similar ischemia/reperfusion injury (IRI) to that observed in younger grafts. 11 Under this policy, survival and postoperative complications rates resulting from the usage of older donors were comparable with those achieved with younger donors.
Some important aspects differentiate our study from most of the relevant papers on this topic. This is one of the largest single- center experiences of LT with donors older than 70 years, whereas many other studies are based on more limited populations. 5, 8, 12, 13, 16 In addition, we reported a long follow-up period, whereas the majority of other analyses showing even excellent outcomes by using old donors were limited to short or middle-term observations. Lastly, our investigation comprised all types of transplants, whereas most of the published series included primary, isolated, and whole liver transplants. [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] Probably, the peculiarity of our study resides in the absence of a predetermined selection among recipients from younger and older donors. This is primarily expressed by the pretransplant MELD score, which was significantly higher in recipients from older donors in the more recent period.
Annals of Surgery
It has repeatedly been pointed out that ECDs should be allocated to recipients without excessive deterioration of liver function or multiple indicators of poor post-LT outcome. 8, 10, 12, 13, [15] [16] [17] [18] [19] [20] [21] 44 Very few studies matched septuagenarian donors with recipients with relatively high MELD score, but again they did not consider all types of transplants, they included limited populations without expected surgically complex procedures, and they had relatively short followup periods. 8, 16 In a recent study performed at 65 US Centers from 2007 to 2011, and derived from the Scientific Registry of Transplant Recipients, the authors compared 540 patients transplanted with donors aged !70 years, with 10,473 recipients from donors aged <60 years. 45 The first group had significantly longer CIT, lower MELD score (17 vs 19) , and fewer HCV-positive recipients, inpatients at the time of LT, and patients with pre-LT hemodialysis. Survival of older grafts was significantly lower (slightly less than 65% at 5 years) than the counterpart. Our experience over a similar time period (2004) (2005) (2006) (2007) (2008) (2009) (2010) showed somewhat opposite data, with shorter CIT and worse conditions of recipients from older versus younger donors. However, graft survival rates were similar to those of the above study.
In general, despite an apparently unfavorable setting, our results in terms of 5-year graft survival, especially in the second period, rank among the best reported by the few authors who evaluated donors !70 years with this same time-point estimation, and ranging between 48% and 79%. 4, [12] [13] [14] [15] [16] Two important studies showed that the D-MELD is able to identify patients at excessively high risk of poor posttransplant outcome. 19, 20 Choosing the D-MELD cut-off used in an Italian cohort, 20 we demonstrated that our results represent an exception, as graft survival rates were comparable between patients with D-MELD lower or higher than 1628. Among our patients with D-MELD >1628, 5-year graft survival was 68.6%, whereas a survival between 50% and 60% should be expected for D-MELD !1600 according to the model of Halldorson et al. 19 Avolio et al 20 showed that a futile transplant (ie, expected 5-year patient survival <50%) is predicted by D-MELD >1750 in HCV-positive patients, whereas we reported 62% survival in this category.
To further investigate the impact of other predictive models of posttransplant survival, we analyzed DRI and BAR scores, which are commonly referred to in the transplant community to assess the risk inherent to donor characteristics, and to a specific donor/recipient combination. 21, 38 Possibly, in relation to our more recent policy of donor management, only BAR score >18 (indicating 98% mortality in the original study) independently affected the outcome. It should be noted that the age cut-off identified for this score is 60 years, and that 5 other variables are included in the total score, 21 all of which were analyzed separately in our study.
These figures definitely support previous data showing higher survival rates using ECD livers, instead of waiting for the ideal graft. 6, 16, 46 Taking advantage from the long study and follow-up periods, we could reliably verify the correctness of donor management and patient selection by comparing 2 consecutive periods.
In the more recent era, the main donor and patient characteristics were significantly worse than in the earlier one, but these features did not affect the results, which, conversely, improved. The combination of shorter ischemia (less than 9% of cases of CIT >8 hours), fewer cases of moderate-to-severe macrosteatosis and of fibrosis stage >1 in older donors (2% and 4%, respectively), quicker operations, fewer retransplants, and hemotransfusions, in spite of more complex procedures (as expressed by previous upperabdomen surgery), could have balanced older donor age and higher MELD in the more recent years. In this context, the use of machine perfusion before graft implantation will further improve both graft quality and function in the case of ECD organs. 1, 47, 48 In the second period, recipients had a longer posttransplant ICU stay, a higher need for chronic HD, and incidence of biliary complications. The longer ICU stay and greater HD requirement could be explained by the worse preoperative patients' conditions and more frequent renal insufficiency reported in the MELD era, 49 whereas the increased rate of biliary complications might be related to older donor age. 15 However, the proportion of successful treatments of such complications was similar in the 2 study periods.
Together with BAR score, patient HCV-positive status, renal replacement treatments, and transplants performed in the earlier period were the variables with the highest negative impact on post-LT survival. Since older donor age is generally associated with worse outcomes in HCV-positive recipients, 3, 7, 16, 23 the use of liver grafts from very aged donors seems even more reasonable in a future perspective of extended use of newer antiviral agents against HCV infection.
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Rather, given the rising proportion of patients undergoing LT for HCC over the years, and the increase of tumor recurrence as cause of death reported in our cohort, care should be taken so as not to excessively extend the HCC indication criteria for LT. In this light, older donor age has recently been indicated as a possible contributor to higher post-LT HCC recurrence, due to the enhanced oxidative stress caused by IRI. 26 Finally, it may be questioned that the reduced regenerative capacity of the graft could affect not only the early outcome, but also the long-term results. 20, 21, 39 However, the long median follow-up of our series allowed us to exclude a detrimental effect of donor age on liver function and viability late after LT.
In conclusion, this study demonstrates for the first time that the use of very aged donors allows long-term survival rates similar to those permitted by grafts from younger donors, irrespectively of the pretransplant recipient clinical conditions. Normal liver function, graft histology available at procurement excluding moderate-tosevere parenchymal alterations, and ischemia time possibly shorter than 8 hours are key factors for a correct use of old donors. Better results in the near future should be achieved with the advent of preimplantation graft perfusion and effective therapies against HCV infection.
